Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
38,248,685
-
Shares change
-
-2,582,768
-
Total reported value, excl. options
-
$553,055,977
-
Value change
-
-$43,016,176
-
Put/Call ratio
-
41%
-
Number of buys
-
71
-
Number of sells
-
58
-
Price
-
$14.48
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2017
As of 31 Dec 2017 Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) had 180 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 38,248,685 shares of stock of the company.
Largest 10 holders included FMR LLC, BlackRock Inc., Vanguard Group Inc, BB BIOTECH AG, WASATCH ADVISORS INC, MILLENNIUM MANAGEMENT LLC, DIMENSIONAL FUND ADVISORS LP, RHENMAN & PARTNERS ASSET MANAGEMENT AB, SAMLYN CAPITAL, LLC, and STATE STREET CORP.
This table shows 180 institutional shareholders of the security as of 31 Dec 2017.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.